Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin

This publication has 24 references indexed in Scilit:

• Complications of Antiretroviral Therapy in Patients with Tuberculosis: Drug Interactions, Toxicity, and Immune Reconstitution Inflammatory Syndrome
  The Journal of Infectious Diseases, 2007
• Survival Rate and Risk Factors of Mortality Among HIV/Tuberculosis-Coinfected Patients With and Without Antiretroviral Therapy
  JAIDS Journal of Acquired Immune Deficiency Syndromes, 2006
• Treatment for Adult HIV Infection
  JAMA, 2006
• Nevirapine Plasma Exposure Affects both Durability of Viral Suppression and Selection of Nevirapine Primary Resistance Mutations in a Clinical Setting
  Antimicrobial Agents and Chemotherapy, 2005
• Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study
  The Lancet, 2004
• Rifampin and Rifabutin Drug Interactions
  Archives of internal medicine (1960), 2002
• Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients
  AIDS, 2001
• Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study
  The Lancet, 1999
• Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus Infection
  New England Journal of Medicine, 1998
• Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study
  BMJ, 1997